6-O-<2-acetamido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-glucopyranosyl>-D-galactopyranose | 209977-52-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-O-<2-acetamido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-glucopyranosyl>-D-galactopyranose
• 英文别名: O-(β-D-galactopyranosyl)-(1,4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1,6)-D-galactose；β-D-Gal-(1->4)-β-D-GlcNAc-(1->6)-D-Gal；6-O-(2-Acetamido-2-deoxy-4-O-(beta-D-galactopyranosyl)-beta-D-glucopyranosyl)-D-galactopyranose；beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-D-Gal；N-[(2R,3R,4R,5S,6R)-4-hydroxy-6-(hydroxymethyl)-2-[[(2R,3R,4S,5R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide
• CAS: 209977-52-6
• 化学式: C₂₀H₃₅NO₁₆
• 分子量: 545.495
• InChiKey: VZIJAGXHAXHZJU-MRGJSYKYSA-N

物化性质

• 沸点：
  948.5±65.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.9
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  278
• 氢给体数：
  11
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  6-O-<2-acetamido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-glucopyranosyl>-D-galactopyranose 、 2-naphthylamino-6,8-disulfonic acid monopotassium salt 在 sodium hydroxide 、 sodium cyanoborohydride 作用下， 生成
  参考文献：
  名称：

  A new method for sequencing linear oligosaccharides on gels using charged, fluorescent conjugates

  摘要：

  A new method is described for sequencing linear oligosaccharides on gels using charged, fluorescent conjugates. The reducing ends of various mono-, di-, tri-, and tetra-saccharides were conjugated with monopotassium 7-amino-1,3-naphthalenedisulfonate (a fluorescent and negatively charged compound) by reductive amination using sodium cyanoborohydride. The sugar conjugates were purified by preparative gradient polyacrylamide gel electrophoresis followed by a newly developed technique involving their semi-dry transfer to positively charged nylon membranes and elution with sodium chloride. The structures of a monosaccharide- and trisaccharide-conjugate were established by f.a.b.-m.s. and 2D n.m.r. Seven linear oligosaccharide-fluorescent conjugates were treated sequentially with exoglycosidases and with endoglycosidases. Analysis of the products by gel electrophoresis provided sequence information. These methods may be useful for sequencing oligosaccharides that are chemically or enzymically (endoglycosidase) released from glycoproteins, glycolipids, and proteoglycans.

  DOI：

  10.1016/s0008-6215(00)90538-x
• 作为产物：
  描述：

  6-O-<2-acetamido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-glucopyranosyl>-1,2;3,4-di-O-isopropylidene-α-D-galactopyranose 在 三氟乙酸 作用下， 反应 0.25h， 以73%的产率得到6-O-<2-acetamido-2-deoxy-4-O-(β-D-galactopyranosyl)-β-D-glucopyranosyl>-D-galactopyranose
  参考文献：
  名称：

  Syntheses of core chain trisaccharides related to human blood group antigenic determinants

  摘要：

  采用邻苯二甲酰亚胺-氯化物法合成了与人类血型决定因子核心链相关的三糖类化合物，即β-D-Galp-(1 → 3)-β-D-GlcNAcp-(1 → 6)-D-Galp(3)、β-D-Galp-(1 → 3)-β-D-GlcNAcp-(1 → 3)-D-Galp(5)、β-D-Galp-(1 → 4)-β-D-GlcNAcp-(1 → 6)-D-Galp(4)和β-D-Galp-(1 → 4)-β-D-GlcNAcp-(1 → 3)-D-Galp(6)。此外，还报道了这些三糖类化合物的8-甲氧羰基辛基β-糖苷化合物的合成。

  DOI：

  10.1139/v82-012

文献信息

• Präparat zur Wirkstoffapplikation in Kleinsttröpfchenform
  申请人：Cevc, Gregor, Prof. Dr.

  公开号：EP0475160A1

  公开（公告）日：1992-03-18

  Die Erfindung betrifft ein Präparat zur Applikation von Wirkstoffen in Form kleinster, insbesondere mit einer membranartigen Hülle aus einer oder wenigen Lagen amphiphiler Moleküle bzw. mit einer amphiphilen Trägersubstanz versehenen Flüssigkeitströpfchen, insbesondere zum Transport des Wirkstoffes in und durch natürliche Barrieren und Konstriktionen wie Häute und dergleichen. Das Präparat weist einen Gehalt einer randaktiven Substanz auf, der bis zu 99 Mol.-% des Gehaltes dieser Substanz entspricht, durch den der Solubilisierungspunkt der Tröpfchen erreicht wird. Das Präparat eignet sich zur nichtinvasiven Verabreichung von Antidiabetica, insbesondere von Insulin. Die Erfindung betrifft außerdem ein Verfahren zur Herstellung solcher Präparate.

  本发明涉及一种以微小液滴形式施用活性物质的制剂，特别是具有一层或几层两亲性分子或两亲性载体物质的膜状包膜，尤其是用于将活性物质输送到或通过皮肤等天然屏障和收缩物。制剂中边缘活性物质的含量最高可达 99 摩尔%，从而达到液滴的溶解点。该制剂适用于非侵入性给药抗糖尿病药物，特别是胰岛素。本发明还涉及生产这种制剂的工艺。
• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。
• Synthesis with immobilized enzymes of two trisaccharides, one of them active as the determinant of a stage antigen.
  作者：Claudine Augé、Serge David、Cécile Mathieu、Christine Gautheron

  DOI：10.1016/s0040-4039(01)80188-x

  日期：——
• SEQUENTIAL REMOVAL OF MONOSACCHARIDES FROM THE REDUCING END OF OLIGOSACCHARIDES AND USES THEREOF
  申请人：The Biomembrane Institute

  公开号：EP0649427B1

  公开（公告）日：1998-01-28
• Preparation for the application of agents in mini-droplets
  申请人：Cevc Gregor

  公开号：US20070042030A1

  公开（公告）日：2007-02-22

  The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers such as skin and similar materials. The preparation contains a concentration of edge active substances which amounts to up to 99 mol-% of the agent concentration which is required for the induction of droplet solubilization. Such preparations are suitable, for example, for the non-invasive applications of antidiabetics, in particular of insulin. The invention, moreover, relates to the methods for the preparation of such formulations.